- Home
- CCLD vs IMMX Comparison
CCLD vs IMMX Comparison
Compare CCLD & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCLD
- IMMX
- Stock Information
- Founded
- CCLD 1999
- IMMX 2014
- Country
- CCLD United States
- IMMX United States
- Employees
- CCLD N/A
- IMMX N/A
- Industry
- CCLD Computer Software: Prepackaged Software
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- CCLD Technology
- IMMX Health Care
- Exchange
- CCLD Nasdaq
- IMMX Nasdaq
- Market Cap
- CCLD 66.3M
- IMMX 55.3M
- IPO Year
- CCLD 2014
- IMMX 2021
- Fundamental
- Price
- CCLD $3.57
- IMMX $1.76
- Analyst Decision
- CCLD Strong Buy
- IMMX Strong Buy
- Analyst Count
- CCLD 2
- IMMX 1
- Target Price
- CCLD $3.75
- IMMX $7.00
- AVG Volume (30 Days)
- CCLD 115.1K
- IMMX 84.6K
- Earning Date
- CCLD 03-20-2025
- IMMX 03-28-2025
- Dividend Yield
- CCLD N/A
- IMMX N/A
- EPS Growth
- CCLD N/A
- IMMX N/A
- EPS
- CCLD N/A
- IMMX N/A
- Revenue
- CCLD $111,014,000.00
- IMMX N/A
- Revenue This Year
- CCLD N/A
- IMMX N/A
- Revenue Next Year
- CCLD $1.47
- IMMX $600.00
- P/E Ratio
- CCLD N/A
- IMMX N/A
- Revenue Growth
- CCLD N/A
- IMMX N/A
- 52 Week Low
- CCLD $1.01
- IMMX $1.26
- 52 Week High
- CCLD $4.84
- IMMX $3.80
- Technical
- Relative Strength Index (RSI)
- CCLD 45.17
- IMMX 31.71
- Support Level
- CCLD $3.90
- IMMX $1.85
- Resistance Level
- CCLD $4.75
- IMMX $2.14
- Average True Range (ATR)
- CCLD 0.33
- IMMX 0.12
- MACD
- CCLD -0.06
- IMMX -0.02
- Stochastic Oscillator
- CCLD 17.48
- IMMX 8.43
About CCLD CareCloud Inc.
CareCloud Inc is a healthcare information technology company. It provides a full suite of proprietary cloud-based solutions and related business services. Its Software-as-a-Service platforms include practice management (PM), electronic health record (EHR), business intelligence, telehealth, patient experience management (PXM) solutions, and robotic processing automation (RPA) bots, along with complementary software tools and business services such as revenue cycle management (RCM), premiere healthcare consulting and implementation services, and on-demand workforce staffing capabilities for high-performance medical groups and health systems nationwide. The operating segments of the group are Healthcare IT, which is the key revenue generating segment, and Practice Management.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.